Several analysts have recently updated their ratings and price targets for Illumina (NASDAQ: ILMN):

  • 7/10/2017 – Illumina had its “underweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $122.00 price target on the stock, up previously from $115.00.
  • 7/5/2017 – Illumina was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/3/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $197.84 price target on the stock.
  • 6/27/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $197.84 price target on the stock.
  • 6/24/2017 – Illumina was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/21/2017 – Illumina was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $197.84 price target on the stock.
  • 6/12/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $197.84 price target on the stock.
  • 5/31/2017 – Illumina was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $197.84 price target on the stock.
  • 5/23/2017 – Illumina was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $197.84 price target on the stock.

Illumina, Inc. (NASDAQ ILMN) opened at 171.74 on Tuesday. Illumina, Inc. has a one year low of $119.37 and a one year high of $189.48. The company has a 50 day moving average of $177.31 and a 200-day moving average of $165.72. The company has a market cap of $25.07 billion, a P/E ratio of 34.76 and a beta of 0.84.

Illumina (NASDAQ:ILMN) last posted its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $598 million for the quarter, compared to analyst estimates of $590.51 million. Illumina had a net margin of 30.75% and a return on equity of 21.21%. Illumina’s revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.71 EPS. On average, equities analysts expect that Illumina, Inc. will post $3.63 earnings per share for the current fiscal year.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the business’s stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $184.14, for a total value of $3,682,800.00. Following the transaction, the director now directly owns 539,176 shares in the company, valued at approximately $99,283,868.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of the business’s stock in a transaction dated Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total transaction of $300,995.63. Following the completion of the transaction, the senior vice president now owns 10,936 shares in the company, valued at $2,045,797.52. The disclosure for this sale can be found here. Insiders sold a total of 110,248 shares of company stock worth $19,720,123 over the last quarter. 1.60% of the stock is currently owned by company insiders.

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Receive News & Ratings for Illumina Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc and related companies with MarketBeat.com's FREE daily email newsletter.